Skip to main content
OpenTrials
Completed

NCT Number: NCT02816203

Vacuum Device for Hemostasis in Obstetrics and Gynecology

Postpartum hemorrhage (PPH), is the leading cause of maternal mortality and is responsible for approximately 25% of maternal mortality deaths.It is defined as blood loss in excess of 500 ml following vaginal childbirth. Primary (immediate) PPH occurs within the first 24 hours after delivery.

In clinical practice, if after giving birth, the placenta is not expelled naturally, an active management should be triggered. After obstetric maneuvers therapeutic, options begin with uterotonic treatments before considering invasive treatments such as embolization, vessel ligation and hysterectomy. However, the morbidity associated with these techniques and the desire to preserve fertility mean that new therapeutic solutions have been conceived, which has recently led to the development of an innovative intrauterine hemostasis medical device : a hemostatic intrauterine suction cup.

Assuming that postpartum hemorrhages are mainly due to uterine atony, we propose in this biomedical research, the study of a new medical device. Our hypothesis is that the uterine walls will append to the walls of the suction cup after the latter is put under vacuum. The actuation of the suction cup will lead to the aspiration of all sides of the uterus.

Considering that postpartum haemorrhage is an emergency situation where vital prognosis of the patient is engaged, we selected to collect the consent of the patient using an emergengy procedure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Postpartum Hemorrhage Administration of Sulprostone Female Urogenital Diseases and Pregnancy Complications Hemorrhage Obstetric Labor Complications Pathologic Processes Pathological Conditions, Signs and Symptoms Postpartum Hemorrhage Pregnancy Complications Puerperal Disorders Urogenital Diseases Uterine Hemorrhage Vaginal Childbirth

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Grenoble

Grenoble, 38043, France

About this study

In this study, as a first pass in human of this innovative non CE marked medical device, we aim to demonstrate the feasibility of using the hemostatic intrauterine suction cup for patients who present primary PPH (blood loss ≥ 500ml) after a vaginal delivery requiring administration of Nalador®. We will evaluate the placement of hemostatic suction cup in the uterus, the application of vacuum and its removal from the uterus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women between 18 and 45 years old
  • patient under loco-regional anesthesia
  • patient who presents primary postpartum hemorrhage (blood loss ≥ 500ml) after a vaginal childbirth requiring administration of Nalador®.
  • affiliation to the French social security system or equivalent
  • patient who has signed a consent to participate

Exclusion criteria

  • patient with a uterine malformation
  • patient allergic to silicon
  • patient under general anesthesia
  • patient who delivered via caesarean section
  • patient with fever or suspected infection during labor
  • person deprived of freedom by judicial or administrative decision
  • person hospitalized without their consent
  • person under legal protection
  • person hospitalized for psychiatric care

Treatment and study plan

Hemostatic Intra-Uterine suction cup

Device

The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.

Primary outcomes

  1. Evaluation of the feasibility of using the hemostatic intrauterine suction cup in patients who present primary PPH (blood loss ≥ 500ml) after a vaginal childbirth requiring the administration of Nalador®.

    Time frame: 36 month

    The primary outcome is composite and consists of 3 the following component outcomes:

    • Qualification of success or failure of the introduction of the suction cup in the uterine cavity
    • Qualification of success or failure to create negative pressure in the suction cup. The negative pressure is validated if vacuum is maintained for at least 30 seconds.
    • Qualification of success or failure of removing the suction cup in its entirety.

    The feasibility of using the suction cup will be validated if success is obtained for the 3 component outcomes.

Secondary outcomes

  1. Evaluation of the ease of the placement of the suction cup by the clinician

    Time frame: 36 month

    Visual quantitative satisfaction scale

  2. Evaluation of whether the bleeding stops after each time the suction cup is put under vacuum. For each patient, the cup may be put once or twice under vacuum.

    Time frame: 36 month

    Subjective evaluation of whether bleeding stops by the clinician after each time the suction cup is put under vacuum.

  3. Evaluation of the ease of removal of the suction cup by the clinician

    Time frame: 36 month

    Visual quantitative satisfaction scale

  4. Quantification of blood loss during delivery

    Time frame: 36 month

    Volume of blood collected in the container of the pump and in the collection bag from the beginning of the delivery until the removal of the suction cup

  5. Evaluation of the number of patients for whom invasive treatment is necessary in order to stop the bleeding

    Time frame: 36 month

    Number of patients for whom embolization or surgery is indicated

  6. Assessment of the duration of time required to place and remove the suction cup

    Time frame: 36 month

    Time duration for the placement and removal of the suction cup

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Collaborators

  • Clinical Investigation Centre for Innovative Technology Network
  • HEMOSQUID

Registry information

Official study title

Vacuum Device for Hemostasis in Obstetrics and Gynecology. Feasibility Study for Postpartum Hemorrhage

Acronym: HEMOGYN2

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Jun 28, 2016
Registry last updated
Mar 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.